Idiopathic pulmonary fibrosis (IPF) is a progressive, deadly disease with a major impact on the lives of patients [1]. Symptom burden and quality of life (QoL) can be assessed with patient-reported outcome measures (PROMs). In the past decade, PROM use was increasingly advocated to capture the impact of treatments and interventions on patients’ symptoms and wellbeing [2]. PROMs are often lengthy, on paper, and with difficult scoring systems, hampering direct use in clinical practice [2]. Thus, there is a need for easy-to-use PROMs in IPF and other interstitial lung diseases (ILDs), both for clinical trials and daily practice.

特发性肺纤维化 (IPF) 是一种进行性、致命的疾病，对患者的生活产生重大影响。1]。症状负担和生活质量 (QoL) 可以通过患者报告的结果测量 (PROM) 进行评估。在过去的十年中，越来越多地提倡使用 PROM 来捕捉治疗和干预措施对患者症状和健康的影响 [2]。PROM 通常在纸面上很冗长，评分系统也很困难，妨碍了在临床实践中的直接使用 [2]。因此，在 IPF 和其他间质性肺病 (ILD) 中需要易于使用的 PROM，用于临床试验和日常实践。